Impfen Pro & Contra - Das Handbuch für die individuelle Impfentscheidung

autism diagnosis, NHIS 1997–2002. J Toxicol Environ Health A 2010, 73 (24): 1665–1677
    Galler, A., Rothe, U., Stange, T., Kunath, H., et al.: Häufigkeit und klinische Charakteristika des Diabetes mellitus Typ 1 im Kindesalter in Sachsen. Monatsschr Kinderheilkd 2004, 152: 163–168
    Garay, P. A., McAllister, A. K.: Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci 2010, 2: 136
    Garenne, M., Leroy, O., Beau, J. P., Sene, I.: Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 1991, 338 (8772): 903–907
    Geier, D. A., Geier, M. R.: A one year follow-up of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System ( VAERS ) database. Clin Exp Rheumatol 2002, 20 (6): 767–771
    Geier, M. R.: Neurodevelopmental disorders after thiomersal-containing vaccines: a brief communication. Ex Biol Med 2003, 228 (6): 660–664
    Geier, D. A., Geier, M. R.: A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit 2005a, 11 (4): 160–170
    Geier, D. A., Geier, M. R.: A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005b, 38 (4): 295–301
    Geier, D. A., Jordan, S. K., Geier, M. R.: The relative toxicity of compounds used as preservatives in vaccines and biologics. Med Sci Monit 2010a, 16 (5): SR 21–27
    Geier, D. A., Young, H. A., Geier, M. R.: Thimerosal exposure & increasing trends of premature puberty in the vaccine safety datalink. Indian J Med Res 2010b, 131: 500–507
    Geissler, E.: SV -40 and human brain tumors. Progress in Medical Virology 1990, 37: 211–222
    Gherardi, R. K., Coquet, M., Chérin, P., Authier F. J., et al.: Macrophagic myofasciitis: an emerging entity. Lancet 1998, 352: 347–352
    Gherardi, R. K.: Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurol 2003, 159 (2): 162–164
    Gherardi, R. K., Authier, F. J.: Macrophagic myofasciitis: characterization and pathophysiology. Lupus 2012, 21 (2): 184–189
    Giangaspero, M., Vacirca, G., Harasawa, R., Büttner, M.: Genotypes of pestivirus RNA detected in live virus vaccines for human use. J Vet Med Sci 2001, 63 (7): 723–733
    Girard, M.: Hepatitis-B universal vaccine. Red Flags, 2.5.2006. http:// www.rolandsimion.org/ IMG /pdf/Learning_from_French_experience.pdf (Zugriff 23. 11. 2011). Deutsche Übersetzung: www.impfo.ch/pdf-dokumente/GirardM_RedFlag_ HBV -I+ MS .pdf (Zugriff 23. 11. 2011)
    Glaser, S. L., Keegan, T. H., Clarke, C. A., Trinh, M., et al.: Exposure to childhood infections and risk of Epstein-Barr virus-defined Hodgkin’s lymphoma in women. Int J Cancer 2005, 115 (4): 599–605
    Glassman, P., Hunter-Hayes, J., Nakamura, T.: Pharmaceutical advertising revenue and physician organizations: how much is too much? Western J of Med 1999, 171: 234–239
    Göttler, M., et al.: Unerwünschte Arzneimittelwirkungen – Zu viele Ärzte sind »meldemüde«. Dtsch Ärzteblatt 1999, 96, 25: 1704–1706
    Guardian, The: Medical studies rubbish. 24.8.1998
    Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., et al.: Adjuvants – a balance between toxicity and adjuvanticity. Vaccine. 1993, 11 (3): 293–306
    Gupta, R. K., Rost, B. E., Relyveld, E., Siber, G. R.: Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 1995, 6: 229–248
    Hahnemann, S.: Organon der Heilkunst. Richard Haehl, 6. Aufl. 1921, Karl Haug, Heidelberg, Neuaufl. 1987
    Havarinasab, S., Hultman, P.: Alteration of the spontaneous systemic autoimmune disease in ( NZB x NZW )F1 mice by treatment with thimerosal (ethyl mercury). Toxicol Appl Pharmacol 2006, 214 (1): 43–54
    Heidary, N., Cohen, D. E.: Hypersensitivity reactions to vaccine components. Dermatitis 2005, 16 (3): 115–120
    Hengst, B., Kazim, H., Volkery, C.: Regierungs-Sponsoring – Wohltäter ohne Namen. Spiegel Online 17.1.2007. http:// www.spiegel.de/wirtschaft/0,1518,460427,00.html (Zugriff 21. 11. 2011)
    Heppner, F. L., Goebel, H., Rieke, H. E.: Impfsicherheit heute: Makrophagen-Myofasziitis. Dtsch Arztebl Int 2009, 106 (14): 248. http:// www.aerzteblatt.de/archiv/63979 (Zugriff 24. 2. 2012)
    Hernan, M. A., Jick, S. S., Olek, M. J., Jick, H.: Recombinant hepatitis B vaccine and the risk of